Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once
daily (QD), compared with placebo, in addition to standard of care, in patients with type 2
diabetes mellitus and acute coronary syndrome.